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ORIGINAL ARTICLE
Enteropathogenic Viruses: Triggers for Exacerbation in IBD?
A Prospective Cohort Study Using Real-time Quantitative
Polymerase Chain Reaction
Gwen M.C. Masclee, MD,* ,† John Penders, PhD,†,‡ Marieke Pierik, MD, PhD,* ,‡ Petra Wolffs, PhD,†,‡
and Daisy Jonkers, PhD*,‡
Background: While the role of bacteria as an etiological factor triggering relapse in inflammatory bowel disease (IBD) has been studied extensively,
little is known of the role of enteric viruses. We aimed to prospectively study the prevalence and risk factors for common enteropathogenic viruses in IBD
patients in relation to disease activity.
Methods: IBD patients visiting the outpatient clinic of the Maastricht University Medical Center were included in a prospective cohort with a follow-up
of 1 year. Every 3 months and during relapses, fecal samples, demographic, and clinical data were collected and disease activity was scored. A fecal
sample from patients at baseline (Crohn’s disease [CD] n ¼ 170, ulcerative colitis [UC] n ¼ 116) and an additional sample from a subgroup with
changing disease activity during follow-up (CD n ¼ 57, UC n ¼ 31) were analyzed for the presence of rotavirus, norovirus GI and GII, human astrovirus,
and adenovirus using quantitative polymerase chain reaction (qPCR).
Results: Overall viral pathogen detection, defined by the detection of at least one of the studied viruses, at baseline was 5.2% and differed neither
between CD (6.5%) or UC patients (3.4%) (P ¼ 0.20), nor between active disease (4.7%) and remission (5.5%) (P ¼ 0.79). Within the subgroup of
patients with changing disease activity no association was found between overall viral pathogen detection and disease activity (P ¼ 0.39). Using
multivariate logistic regression, age, gender, disease subtype, disease activity, medication, and season of sampling were not associated with overall viral
pathogen detection.
Conclusions: Enteropathogenic viruses are not frequently observed in a consecutive cohort of IBD patients and are not a common trigger for active
disease in daily clinical practice.
(Inflamm Bowel Dis 2013;19:124–131)
Key Words: inflammatory bowel disease, virus, etiology, enteric pathogen, real-time polymerase chain reaction
O ur knowledge of the role of the intestinal microbiota inhealth and disease is rapidly increasing.1–3 This has re-
sulted in more detailed insight of microbial involvement in the
pathogenesis of inflammatory bowel diseases (IBD). This is
based on the presence of high mucosal bacterial numbers4 and
findings that diversion of the fecal stream5 and antibiotic ther-
apy6 resulted in decreased disease activity. Murine colitis
models further support the importance of the microbiota in
the induction and perpetuation of intestinal inflammation.7
Although a dysbalance of the (fecal and mucosal) commensal
microbiota has been demonstrated in patients with IBD,4,8,9
and differences in microbiota in relation to disease subtype
is described,4 so far no specific bacterial species or groups
have been identified to be causative or associated with an
exacerbation. In addition to a putative role of commensal bac-
teria, gastrointestinal pathogens have been suggested to induce
intestinal symptoms and/or inflammation. Associations have
been reported between acute gastroenteritis and onset or ex-
acerbations of IBD.10–12 Considering a potential role for
microbial pathogens in inducing flares in IBD, one should take
into account that gastrointestinal infections are caused most
frequently by enteric viruses such as rotavirus and norovirus
instead of bacteria.13,14 Recent experiments in animals do
point to a role of enteric viruses in the progression of colitis.
It was shown that murine norovirus worsened colitis induced
by Helicobacter bilis.15 In another mouse model, murine nor-
ovirus induced Paneth cell dysfunction in genetically suscep-
tible mice.16,17 In human studies, cytopathic effects have been
observed in cell monolayers induced by administration of ho-
mogenates of tissue obtained from Crohn’s disease (CD)
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patients. These cytopathic effects have been attributed to
a virus.18,19 However, these observations were not specific,
since similar effects have been obtained with isolates of tissue
retrieved from patients with other chronic intestinal disor-
ders.20 Other investigators have not been able to confirm these
findings21,22 and sero-logical studies did not find an associa-
tion between serocon-version of antibodies against rotavirus,
Norwalk virus (currently named norovirus), or adenovirus and
clinical relapse or IBD subtype.23,24 No association was
observed between the presence of antibodies against adenovi-
rus and regional enteritis in ulcerative colitis (UC)22,24,25 or
antibody prevalence and titer to rotavirus or Norwalk virus in
CD compared to matched controls.26
A recent retrospective study evaluating noroviruses in
pediatric IBD patients could not specify a role for norovirus in
initiation or exacerbation of IBD.27 Unfortunately, the data
were based on very small numbers (i.e., nine patients) and
a traditional diagnostic technique (i.e., enzyme immunoassay)
was used. Although up to now studies in humans have not
been able to demonstrate a potential role for enteric viruses
in IBD, these interpretations of data were hampered by short-
comings in the diagnostic technique or in sample size. Pro-
spective studies using state of the art molecular techniques in
larger sets of adult IBD patients are currently lacking. Such
state of the art diagnostic techniques have proved to be very
accurate and concordant in viral detection rate when compared
to traditionally used methods.28,29 Real-time quantitative poly-
merase chain reaction (qPCR) is emerging as a method for
detection of enteric viruses in feces.30–32
Considering the possible limitations of the previous
human studies, and the potential role of enteric viruses in the
progression of colitis in experimental mice models, further
studies are warranted to investigate whether enteric viruses are
associated with development of active disease in IBD. This
holds especially true for patients while on immunosuppressive
agents. Therefore, we aimed to investigate the prevalence of
common enteric viruses in relation to disease activity in
a consecutive prospective cohort of IBD patients, and second,




Between August 2009 and November 2010, consecutive
IBD patients visiting the outpatient IBD clinic of our combined
secondary and tertiary hospital (Maastricht University Medical
Centre) were asked to participate and upon agreement were
included in a prospective cohort study with 1-year follow-up after
inclusion. The diagnosis of CD or UC was based on endo-scopic,
histological, and/or radiological findings. Patients visited the
hospital every 3 months and at time of relapse, during which
fecal samples, demographic, and clinical data were collected
using standardized sampling and registration protocols.
Data of concomitant use of medication, smoking status
(current smoker, quit smoking within or over 6 months, never
smoked), body mass index (BMI), disease duration since
diagnosis, and disease phenotype were obtained using the
computer-based medical registration databases. Disease activity
was scored by the Harvey–Bradshaw index for CD patients,33
(remission defined as score ,5), the Simple Clinical Colitis
Activity Index for UC patients34 (remission defined as score
,3), and the Pouchitis Disease Activity Index for UC patients
with a pouch35 (remission defined as solely clinical score #2, or
solely endoscopic score #1, or total score, combination of clin-
ical and endoscopic score #4).
Patients were provided with a small plastic container
(Fisher Scientific, Landsmeer, The Netherlands) and instructed
to collect a fecal sample on the evening before or the morning of
each visit and to store the sample at 48C. Upon arrival at the
laboratory, undiluted feces was frozen at 2808C within 24 hours
after defecation.
Fecal samples from the inclusion visit of all patients were
used for further analyses in the present study (i.e., baseline
cohort). Furthermore, from a subgroup of patients with changing
disease activity during follow-up, a second sample was evaluated
(i.e., follow-up cohort).
Viral Diagnostics
For the present study, the most common enteric viruses,
i.e., rotavirus, norovirus G I and II, human astrovirus, and
adenovirus13,14,36 were analyzed. Before RNA and DNA extrac-
tion, all samples were spiked with murine cytomegalovirus
(mCMV) RNA, which was used as an extraction and amplifica-
tion control. The procedure for DNA and RNA isolation has been
described in detail elsewhere.28
Briefly, feces was homogenized with the MagNA Lyser
(Roche Diagnostics, Almere, The Netherlands). DNA and RNA
were isolated using the MagNA Pure total NA extraction kit by
the MagNA Pure LC system (Roche Diagnostics).
The detection of the viruses under study was conducted by
real-time PCR using the primers and probes described in Table 1.
For the detection of RNA viruses, this was preceded by a reverse
transcription (RT) step using TaqMan reverse transcriptase reagents
by utilizing random hexamers (Applied Biosystems, Foster City,
CA) and consisted of 10 minutes at 258C, 30 minutes at 488C,
5 minutes at 958C, and finally a cooling phase down to 48C.
The real-time PCR mix for each reaction consisted of
10 mL isolated DNA, 900 nM of both the forward and reverse
primers, 300 nM probe, 12.5 mL Absolute quantitative PCR mix
(Abgene, Epsom, UK), and additional NASBA water to reach
a final reaction volume of 25 mL. The PCR protocol consisted
of 15 minutes at 958C, followed by 42 cycles of 15 seconds at
958C and 1 minute at 608C and was reported in more detail pre-
viously.28 The quality of the assays was ensured by positive and
negative controls as well as a test on amplification inhibition in
Inflamm Bowel Dis  Volume 19, Number 1, January 2013 Enteropathogenic Viruses
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each sample by an external amplification control (mCMV). Arti-
ficial RNA controls were constructed using pGEM-3Z vectors
containing T7 RNA polymerase promoters flanking the multiple
cloning region (Promega, Leiden, The Netherlands) into which
the respective amplicons were cloned. Using T7 RNA polymer-
ase, RNA constructs containing the amplicons were generated and
used as positive RNA controls.
Samples were considered positive when a virus was detected,
irrespective of the Ct value at which the virus was detected. The
overall viral pathogen detection was defined by the detection of at
least one of the studied viruses.
Statistical Analysis
The chi-square test was used to compare dichotomous
variables between subgroups of patients. In case of too-small
numbers, Fisher’s exact test was performed.
Multivariate logistic regression analyses were performed
for the identification of risk factors (disease subtype [CD or UC],
disease activity [active disease or remission], gender, immuno-
suppressive therapy [corticosteroids, methotrexate and/ or thio-
purines], anti-tumor necrosis factor alpha [TNF-a] therapy, age,
and season of sample collection) for overall viral pathogen detec-
tion. Classification of sample collection per season was based on
the date of fecal sample collection.
McNemar’s test was used to examine the association between
disease activity and overall viral pathogenic detection within the
subgroup of subjects of whom both a fecal sample during active
disease and remission were available (follow-up cohort).
Statistical analyses were performed using SPSS v. 18.0
(Chicago, IL). Statistical significance was defined as P , 0.05.
Ethical Considerations
The study was approved by the Medical Ethics Committee
of the Maastricht University Medical Centre, Maastricht, and
written informed consent was obtained from all patients.
RESULTS
Patients
A total of 323 patients were included in the IBD study cohort.
A baseline fecal sample was available from 286 patients (baseline
cohort). Baseline characteristics of these patients are shown in
Table 2. Mean age at baseline was 46.2 years (SD 15.2), with mean
disease duration of 12.4 years (SD 9.9). CD and UC were diagnosed
in 59% and 41% (including 15% with an ileal-anal pouch) of the
study population, respectively. Active disease was present in 85
patients (29.7%), and was comparable in CD (33.5%) versus UC
(25.0%) patients. During the 1-year follow-up period, disease activ-
ity changed over time in 94 patients, of whom 88 (follow-up cohort)
provided fecal samples during both remission and relapse of disease.
Enteric Viruses
Baseline
The overall viral pathogen detection at baseline was
5.2% in all IBD patients and did not differ significantly
TABLE 1. Sequences of Primers and Probes Used for the Detection of Enteric Viruses
Target Organism Primer/Probe Sequence (50–30) Reference
Adenovirus Forward primer GCCCCAGTGGTCTTACATGCACATC 31
Reverse primer GCCACGGTGGGGTTTCTAAACTT 31
Probe FAM-TGCACCAGACCCGGGCTCAGGTACTCCGA-BQI 31
Human astrovirus Forward primer TCTYATAGACCGYATTATTGG 63
Reverse primer TCAAATTCTACATCATCACCAA 63
Probe FAM-CCCCADCCATCATCATCTTCATCA-TAMRA 63
Norovirus GI Forward primer CGYTGGATGCGNTTYCATGA 63
Reverse primer CCTTAGACGCCATCATCATTTAC 63
Probe FAM-TYGCGRTCTCCTGTCCA-MGBNFQ 63
Norovirus GII Forward primer CARGARBCNATGTTYAGRTGGATGAG 63
Reverse primer TCGACGCCATCTTCATTCACA 63
Probe VIC-AGATYGCGATCSCCCTC-MGBNFQ 63
Rotavirus Forward primer ACCATCTTCACGTAACCCTC 15 64
ACCATCTACACATGACCCTC (2nd forward primer)
Reverse primer CACATAACGCCCCTATAGCC 64
Probe FAM-ATGAGCACAATAGTTAAAAGCTAACACTGTTCAA-BQ1 64
FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine; BQ1, black hole quencher 1; MGBNFQ, minor groove binding nonfluorescent quencher; VIC, fluorescent label
(Applied Biosystems).
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between CD (6.5%) and UC (3.4%) patients (P ¼ 0.20)
(Fig. 1). Adenoviruses were detected more frequently (3.8% in
IBD patients) compared to the other viruses, without any pref-
erence for disease subtype (P ¼ 0.52). Rotavirus and norovirus
GI were detected in 1.0% and 0.3%, respectively. Human astro-
virus and norovirus GII were not detected in any of the
fecal samples at baseline. No coinfections were observed. Prev-
alences of the single viruses were not different between UC
and CD.
The prevalence of the single viruses and overall viral
pathogen detection in CD, UC, and IBD patients in relation to
disease activity is shown in Table 3. Comparing active patients
with those in remission, no significant differences were found for
overall viral pathogen detection (P ¼ 0.79), nor for single enteric
viruses.
As no differences for overall viral pathogen detection
were found between CD and UC, the multivariate analysis was
performed with the total IBD population, including disease
subtype as covariate (Table 4). No statistically significant
associations were found between overall viral pathogen detec-
tion and disease subtype, disease activity, gender, age, immu-
nosuppressive therapy, anti-TNF-a therapy, or season of
sample collection. The timing of sample collection of the base-
line cohort was equally distributed over the seasons (data not
shown).
Follow-up Cohort
From 88 subjects subsequent samples were analyzed
during follow-up. From 39 patients (27 CD and 12 UC) disease
activity changed from inactive toward active disease and from
49 patients (30 CD and 19 UC) from active toward inactive
disease during follow-up. The mean time between subsequent
samples in both groups was 110 (SD 671) and 153 (SD 687)
days, respectively.
In this follow-up cohort where alterations in disease activity
occurred during follow-up, overall viral pathogen detection did
not differ between active disease (4.0%) and remission (7.7%)
(McNemar’s test for paired proportions, P ¼ 0.39). Within the
group of active disease at baseline, two CD patients tested posi-
tive for an enteric virus, whereas during follow-up in three CD
and three UC patients a virus was detected in the fecal sample
taken during remission. Only one CD patient had two consecutive
positive fecal samples for rotavirus: at baseline (i.e., active dis-
ease) as well as during subsequent remission after a follow-up of
104 days. Within the group of remission in which two CD patients
and one UC patients tested positive for an enteric virus at base-
line, during follow-up an enteric virus was detected in the fecal
sample taken during active disease in two CD patients and one
UC patient.






Active disease 57 (33.5) 29 (25.0)
Remission 113 (66.5) 87 (75.0)
Male 60 (35.3) 62 (53.4)
Mean age in yrs (SD) 44.0 (15.0) 49.4 (14.9)
Disease duration in yrs (SD) 12.2 (10.7) 12.5 (8.6)
Disease phenotype
Nonpenetrating, nonstricturing 118 (69.4)
Stricturing 29 (17.1)
Penetrating 16 (9.4)
Stricturing and penetrating 7 (4.1)
Disease location
Colon 38 (22.4)
Small bowel only 48 (28.3)
Ileocolonic 84 (49.4)
Medication use 144 (84.7) 105 (90.5)
Immunosuppressive therapy 124 (72.9) 53 (45.7)
Thiopurin 60 (35.3) 30 (25.9)
Azathioprin 35 (20.6) 14 (12.1)
Mercaptopurin 25 (14.7) 16 (13.8)
Methotrexate 9 (5.3) 4 (3.4)
Anti-TNF alpha therapy 75 (44.1) 24 (20.7)
Infliximab 55 (32.4) 24 (20.7)
Adalimumab 19 (11.2)
Other 1 (0.6)
Corticosteroids 25 (14.7) 10 (8.6)
Prednisone 4 (2.4) 7 (6.1)
Budesonide 21 (12.4) 4 (3.4)
Aminosalicylates
Systemically 33 (19.4) 61 (52.6)
Locally 2 (1.2) 18 (15.5)
Immunosuppressive agents therapy
none 46 (27.1) 63 (54.3)
1 86 (50.6) 39 (33.6)
$2 38 (22.4) 14 (12.1)
CD, Crohn’s disease; UC, ulcerative colitis.
FIGURE 1. Prevalence and distribution of the detected separate viruses
in CD, UC, and all IBD patients at baseline.
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DISCUSSION
To our knowledge, this is the first study investigating the
role of common enteric viruses in a prospective cohort of adult
IBD outpatients by real-time qPCR. We report a low overall
prevalence of enteric viruses in IBD patients. No association
was observed between overall viral pathogen detection and
IBD subtype, disease activity, or use of immunosuppressive
therapy.
The overall viral pathogen detection rate at baseline in
IBD patients is low (5.2%) and did not differ significantly
between CD and UC patients. For comparison, data on enteric
virus prevalences in a community setting using molecular
diagnostic techniques on fecal samples are limited. A study in
a population-based Dutch cohort of asymptomatic subjects
reported a prevalence of 9.1%.13 This prevalence of enteric
viruses is higher than we observed in IBD and may at least
partly be explained by the fact that this population study also tested
for sapovirus. Moreover, 54% of the subjects were children up to
the age of 11 years, which are known to be more susceptible to
enteric viruses17 and the prevalence and fecal shedding of enteric
viruses in children is reported to be higher.37,38 Another study inves-
tigated the prevalence of rotavirus and adenovirus in asymptomatic
subjects in a community setting and reported viral pathogen detec-
tion in 0.1%.39 It should be noted that these findings were based on
latex agglutination tests. When molecular techniques are used, the
prevalences of adenovirus, rotavirus, norovirus, sapovirus, and
human astrovirus in controls is generally higher.29 Despite consider-
able differences in the reported prevalence of enteric viruses related
to diagnostic techniques used and the populations, the low overall
prevalence observed in IBD patients is in agreement with data
obtained in the general population.
In our cohort, the viral detection rate was highest for
adenoviruses (3.8%). This is in line with observations in
patients with acute gastroenteritis13 but is higher in comparison
to healthy controls40 and to the prevalence of enteric adenovirus
(Ead) in gastroenteritis patients.41 However, we cannot
conclude that our reported prevalence can be fully accounted
for by enteric adenoviruses, since we did not use primers spe-
cific for serotype 40 and 41 (Ead). Human astrovirus was not
detected in our study, in line with the low prevalence in healthy




A N¼57 N (%) R N¼113 N (%) A N¼29 N (%) R N¼87 N (%) AN¼86 N (%) R N¼200 N (%)
Rotavirus 2 (3.5) 1 (0.9) 0 0 2 (2.3) 1 (0.5)
Norovirus GI 0 1 (0.9) 0 0 0 1 (0.5)
Norovirus GII 0 0 0 0 0 0
Human astrovirus 0 0 0 0 0 0
Adenovirus 2 (3.5) 5 (4.4) 0 4 (4.6) 2 (2.3) 9 (4.5)
Overall viral pathogen detection 4 (7.0) 7 (6.2) 0 4 (4.6) 4 (4.7) 11 (5.5)
Presented for Crohn’s disease (CD), ulcerative colitis (UC), and all IBD patients during active disease (A) and remission (R).
TABLE 4. Multivariate Analysis for the Identification of
Risk Factors for Overall Viral Pathogen Detection in the
Baseline Cohort (n¼286)
Variables OR 95% CI P-value
Disease subtype
CD 1 —
UC 0.38 0.1121.36 0.14
Disease activity
Remission 1 —
Active disease 1.05 0.3023.60 0.94
Gender
Male 1 —
Female 0.45 0.1421.42 0.17
Age (years) 0.99 0.9521.02 0.45
Immunosuppressive therapy *
No 1 —
Yes 1.76 0.582.35 0.32
Anti-TNF-alpha therapy
No —
Yes 0.26 0.0521.30 0.10
Season
Summer 1 —
Autumn 0.34 0.0422.88 0.32
Winter 0.94 0.1625.49 0.95
Spring 1.59 0.2828.97 0.60
CD, Crohn’s disease; UC, ulcerative colitis; OR, odds ratio; CI, confidence interval.
*Combination of corticosteroids, methotrexate, and/or thiopurines.
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controls,13 but also in acute gastroenteritis patients.41 Norovi-
ruses were anticipated to be observed more frequently. Our data
do not confirm this with a low prevalence at baseline. In follow-
up we detected noroviruses (both GI and GII) in seven samples.
Although the applied real-time PCR method allows for the
determination of an exact viral load (in copies or genome
equivalents), this was not determined in our study, as factors
such as the consistency and water content of the fecal samples
influence the viral load. No correction for these factors was
included in this study because of the small number of viral-
positive samples.
With the application of sensitive molecular methods in
a prospective cohort of IBD patients, we found neither an
association between disease subtype or disease activity with
overall viral pathogen detection nor with the presence of any
of the enteropathogenic viruses studied. Although the results of
several older studies might be limited due to the use of
conventional techniques,20–26 our findings strongly add evidence
to these early reports and assumptions. However, our data are in
contrast to those obtained in mice models, which indicate
a potential role for enteric viruses in the pathogenesis of
IBD.15–17 The low overall viral pathogen detection rate, as found
in our study, however, contradicts the importance of such an
association.
By multivariate analysis no risk factors could be identified,
which was to be expected based on the small number of positive
samples. No seasonal influences regarding sampling were noticed,
considering seasonal variability of separate viruses.41–43 Seasonal
variation in flares of IBD has been suggested, although the results
are inconsistent.44–52 Both findings support our results, and
emphasize the lack of association between viral pathogens and
relapse in IBD.
Following patients consecutively in relation to a change of
disease activity over time, especially the transition from inactive
toward active disease, permitted us to investigate the role of
enteric viruses in triggering relapses of disease. Analysis of
overall viral pathogen detection within subjects with changing
disease activity showed no relation between viral detection and
IBD subtype or disease activity. We identified only one patient in
whom two consecutive samples were positive for rotavirus, with
decreasing quantity over time (data not shown). In the follow-up
cohort the mean time between first and second sample was 129
days and we thereby excluded the presence of chronic viral
infection in the studied patients. In healthy adults viral excretion is
observed with a maximum of 8 weeks after inoculation,53 whereas
chronic viral infection has been reported in severely immunocom-
promised patients.
Whether the risk of serious and/or opportunistic infections
in patients using immunosuppressive, modulating drugs, or anti-
TNF-a agents is increased is currently under debate.54–56 Our
data do not support such an association for enteric viruses in
an unselected prospective cohort of IBD patients from a com-
bined secondary and tertiary hospital, thereby representing daily
clinical practice.57–59 As expected, the follow-up cohort received
significantly more often anti-TNF-alpha therapy (P , 0.001)
and immunosuppressive agents (P , 0.001) (data not shown)
compared to those with only one sample analyzed, presumably
due to the disease activity and severity of patients from the
follow-up cohort.
Even though a significantly higher proportion of patients
receiving anti-TNF-a therapy at baseline had active disease, nei-
ther disease activity nor use of anti-TNF-a therapy influenced
overall viral pathogen detection. It is known that the impact of
thiopurine therapy on the host immune function is mainly through
inhibition of T lymphocytes,60 which are important in the pre-
vention of viral infection. Considering the high number of patients
at baseline using thiopurine therapy, the likelihood for overall
viral pathogen detection in patients using immunosuppressive
therapy use was not increased. The question of whether the use
of specific medication is accompanied by an increased suscepti-
bility for viral infection should be based on a larger group of IBD
patients.
We acknowledge a few limitations of the present study.
First, the period of median viral excretion after infection in adults
was 4 weeks.53 We cannot exclude that patients will have had
a viral infection before attending the clinic. However, patients
experiencing gastrointestinal symptoms, perhaps attributable to
an exacerbation, are instructed to contact our clinic for further
diagnostics and necessary adaptation of therapy. In addition,
patients usually visit the outpatient clinic within an interval of
less than 2 weeks after onset of the first symptoms. Second, the
duration of relapse in patients with active disease at baseline has
not been taken into account. Since we were interested in preva-
lences of enteric viruses in both active and inactive disease and we
furthermore wanted to elucidate the role of viruses in fluctuations
in disease activity, the prospective design and analysis within the
follow-up cohort will have markedly reduced, if not excluded, this
influence.
Within the current study we used a hypothesis-driven
approach targeting the by far most common enteropathogenic
viruses. Although unlikely, given the already low prevalence
of the viruses under study, we cannot rule out the potential
influence of other (less common or unknown) viruses with
certainty.
In this respect, the application of metagenomics to study the
intestinal virome in a more explorative manner may provide
additional insights. The implementation of viral metagenomic
approaches has already increased our knowledge of viruses
inhabiting the human gut, but also has illustrated that the vast
majority of viruses identified from human feces are not animal
viruses but rather bacterial viruses (phages)61 or plant viruses62
derived from contaminated food.
The strength of the current study is that from a large group
of adult IBD patients representative for daily clinical practice,
clinical data and consecutive fecal samples were available for
analyses. Since from a subgroup of patients with alterations in
disease activity additional fecal samples were analyzed, insight
into the potential role of enteric viruses in triggering active disease
Inflamm Bowel Dis  Volume 19, Number 1, January 2013 Enteropathogenic Viruses
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of IBD could be investigated. We used sensitive molecular
diagnostic techniques for viral detection.
CONCLUSION
In this prospective study we report a very low prevalence of
enteric viruses in IBD patients visiting the outpatient clinic. No
risk factors for viral infection were identified. Our findings
indicate that common enteric viral pathogens are not a major
trigger for exacerbations in IBD in daily clinical practice.
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